Unlock instant, AI-driven research and patent intelligence for your innovation.

Functional oligosaccharide-containing composition for treating Alzheimer's disease and preparation method and application thereof

A technology of Alzheimer's disease and composition, applied in the field of biopharmaceuticals, can solve problems such as easy recurrence, large toxic and side effects, and unsatisfactory therapeutic effect

Inactive Publication Date: 2018-07-10
THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs are only symptomatic treatment, the treatment effect is not satisfactory, and the long-term use has serious side effects, and at the same time, they are expensive, easy to relapse after stopping the drug, and cannot reverse or cure AD
In addition, although a large number of clinical trials are devoted to the development of therapeutic drugs targeting the inhibition of Aβ levels, the long-term efficacy and safety of these drugs have not yet been effectively verified
At present, there are no relevant studies and reports on the use of fructooligosaccharides for the treatment of Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The present invention is used for treating Alzheimer's disease composition, comprises each component of following weight:

[0023] composition

Weight (mg)

fructooligosaccharide

88

Bifidobacterium adolescent active factor

6

Hydroxybenzyl Phosphate

6

[0024] Preparation method of bifidobacterium adolescent active factor

[0025] (1) Preparation of seed liquid: Pick a single colony of Bifidobacterium adolescentis LJM-001, the preservation number is CGMCC No.4090, inoculate it in sterilized MRS liquid medium, and culture it anaerobically at 37°C for 24 hours , to obtain Bifidobacterium adolescentis LJM-001 seed solution;

[0026] (2) Fermentation: insert the inoculum amount of step (1) seed liquid into sterilized sterilized 3% peptone, 2% yeast extract, 8% glucose, L-half Cystine hydrochloride 0.05%, ammonium sulfate 0.1%, potassium dihydrogen phosphate 0.1%, dipotassium hydrogen phosphate 0.1%, manganese sulfate 0.02%, mag...

Embodiment 2

[0032] The present invention is used for treating Alzheimer's disease composition, comprises each component of following weight:

[0033] composition

Weight (mg)

fructooligosaccharide

80

Bifidobacterium adolescent active factor

10

Hydroxybenzyl Phosphate

10

[0034] Wherein the preparation method of bifidobacterium adolescent active factor

[0035](1) Preparation of seed liquid: Pick a single colony of Bifidobacterium adolescentis LJM-001, the preservation number is CGMCC No.4090, inoculate it in sterilized MRS liquid medium, and culture it anaerobically at 37°C for 24 hours , to obtain Bifidobacterium adolescentis LJM-001 seed solution;

[0036] (2) Fermentation: insert the inoculum amount of step (1) seed liquid into sterilized 5% peptone by weight percentage, yeast extract 1%, glucose 7%, L-half Cystine hydrochloride 0.5%, ammonium sulfate 0.1%, potassium dihydrogen phosphate 0.2%, dipotassium hydrogen phosphate 0.05%, manga...

Embodiment 3

[0041] Embodiment 3 animal experiments

[0042] The APP / PS1 transgenic AD mouse model was randomly divided into a model group, a treatment group in Example 1, and a fructooligosaccharide treatment group, and wild-type C57BL / 6J mice were used as a normal control group.

[0043] 1. Materials and methods

[0044] 1. Behavioral testing

[0045] 1.1 New object recognition experiment: To examine the memory and exploration ability, the experiment was carried out in 5 days, the mice were allowed to recognize the box environment on the first and second days, and two identical cubes were placed in the box on the third and fourth days to make them familiar with the objects , on day 5, one of the two cubes from the previous day was replaced with a black cone of similar volume and height, by comparing the length of time the mice explored the cube (i.e. the old object) and the cone (i.e. the new object) respectively. Analyze the memory ability of mice.

[0046] 1.2 Spontaneous activity e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a functional oligosaccharide-containing composition for treating Alzheimer's disease. The functional oligosaccharide-containing composition contains oligofructose, a bifidobacterium adolescentis active factor and hydroxybenzyl phosphate. The invention relates to a use of the functional oligosaccharide-containing composition in preparation of drugs for treating Alzheimer's disease. The used raw materials are derived from natural plants and are safe and non-toxic. The preparation method has simple processes and is easy to promote and use. The functional oligosaccharide-containing composition is designed according to a new perspective of preventing and treating Alzheimer's disease through adjusting the intestinal flora, and has an important economic and social significance and a promotion value.

Description

technical field [0001] The invention relates to the use of functional oligosaccharides, in particular to the application of a composition containing functional oligosaccharides in the preparation of medicines for treating Alzheimer's disease, and belongs to the field of biopharmaceuticals. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease with progressive decline in cognitive function as the main clinical manifestation. The age of onset of the disease is mostly after the age of 65, and the average course of the disease is about 8 to 10 years. The clinical manifestations are the chronic and progressive decline of memory, cognition, understanding, judgment and reasoning ability, social adaptability, and personal living ability, and eventually develop into severe dementia. Most of them have an insidious onset, with irreversible progressive cognitive impairment as a typical feature, and some patients may also experience personality changes. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/745A61P25/28C12P1/04A61K31/733A61K31/702A61K31/7016A61K31/661C12R1/01
CPCA61K31/661A61K31/7016A61K31/702A61K31/733A61K35/745C12P1/04C12N1/205C12R2001/01A61K2300/00
Inventor 孙晶刘佳明
Owner THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE